(CDAX, Technology, SMHN GR)



Buy eur 32.00		Value Indicators: DCF: FCF-Value Potential 23e:	32.00	Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	2.3 3.0 2.0 2.0	Description: Leading solution provider for markets advanced packaging integration, LED, MEMS	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2022e
		Market cap:	264.7	Freefloat	100.00 %	Beta:	1.3
Price	EUR 13.86	No. of shares (m):	19.1	Universal Investment	9.60 %	Price / Book:	1.5 x
Upside	130.9 %	EV:	239.7	Luxempart	8.30 %	Equity Ratio:	63 %
		Freefloat MC:	264.7	Teslin	6.70 %		
		Ø Trad. Vol. (30d):	793.51 th	Henderson	5.00 %		

Record bookings include thematically relevant tool orders

Stated Figure	es Q1/20	022:					Comment on Figures:
FY End: 31.12. in EUR m	Q1 22	Q1 22e	Q1 21	yoy 22e	21	уоу	 Revenues up 20% yoy despite a very slow start to the year as a result o component shortages
Order entry Sales EBIT Margin	117.6 63.3 2.1 3.3 %	112.0 59.0 2.3 4.0 %	81.0 52.6 1.4 2.7 %	45 % 350.0 20 % 300.0 46 % 31.0 10.3 %	336.0 263.4 22.6 8.6 %	4 % 14 % 37 %	 As in the past two years, Q1 should represent the quarter with the lowes sales contribution. As expected, the EBIT margin remained at a low level of just above 3% in Q1

SÜSS announced very strong order intake for Q1 2022 while development of revenues and earnings was largely in line with the assumption.

As in Q1 2021, SÜSS registered a **rather low gross margin of 33%** in the first three months. While the gross margin in the lithography area remained at a favourable level of 36%, the group gross margin was diluted by the photomask business with a level of just above 26%, which mostly reflects low segment sales, as shortages led to postponed revenue recognition. On the positive side, SÜSS achieved an increase in its gross margin in the microoptics business by 200bps yoy to 29%. Here, the ramp of the new micro lens array production for automotive headlamps is temporarily burdening the profitability. Yield increases however are being achieved even slightly faster than planned.

Orders of almost EUR 118m (+45% yoy) **represent a new record level** and led to a surge in order backlog to EUR 249m. The bonder segment showed a particularly strong order level (EUR 20m; 73% above 2021 average) as did the photomask business (EUR 41m; >100% above high 2021 average).

In the **bonder segment**, SÜSS achieved an important milestone and gained a first commercial order for its wafer-to-wafer hybrid bonding tool, which will be used in the volume production of microLEDs (follow-up orders are likely). Generally, hybrid bonding is regarded to be one of the most important growth drivers for SÜSS. Besides, SÜSS recorded orders for temporary and permanent bond tools, underpinning the growth expectations for the bonder segment and SÜSS is expecting demand for permanent bonders to accelerate further.

In Q1, SÜSS received orders for its scanner system from two new customers. This adoption is strategically positive as it shows that there should be a general market for such exposure tools besides the main application by SÜSS' lead customer. The CEO confirmed that he now increasingly regards this area as a sustainable growth driver, which could represent upside to the 2025 guidance.

Supply-chain issues represent the greatest source of uncertainty, as component shortages lead to postponed revenue recognition. Nevertheless, SÜSS is sticking to its FY forecast, which already incorporates some caution with regard to shipment delays.


Conclusion: A positive profitability trend is to be expected in the coming quarters. Demand was very strong with thematically important orders for bonders + scanners. Supply-chain issues remain though with no additional visibility. Significant growth should kick in once these issues begin to ease, which is not priced in currently (EV/EBIT 23, 4.6x). **Buy** with unchanged **PT of EUR 32**.

27.5	FY End: 31.12.	CAGR							
21.5 MM n	in EUR m	(21-23e)	2017	2018	2019	2020	2021	2022e	2023e
25 - monthing monthing with his way	Sales	16.1 %	166.5	203.9	213.8	252.1	263.4	300.0	355.0
The show when	Change Sales yoy		-6.2 %	22.5 %	4.8 %	17.9 %	4.5 %	13.9 %	18.3 %
22.5 - Why how he	Gross profit margin		35.7 %	33.0 %	23.3 %	33.2 %	35.8 %	36.0 %	36.0 %
20 -	EBITDA	37.7 %	18.0	15.7	-5.2	28.2	29.6	38.9	56.1
Stranger 1	EBIT	45.3 %	13.9	10.9	-13.8	20.4	22.6	31.0	47.6
17.5 -	Margin		8.3 %	5.3 %	-6.4 %	8.1 %	8.6 %	10.3 %	13.4 %
15 -	EBIT adj.		13.9	10.9	0.5	23.0	22.6	31.0	47.6
15 - V VV	Margin		8.3 %	5.3 %	0.2 %	9.1 %	8.6 %	10.3 %	13.4 %
07/21 09/21 11/21 01/22 03/22 05/22	Net income	44.5 %	6.7	4.8	-16.3	12.3	16.0	21.6	33.4
0//21 09/21 11/21 01/22 03/22 05/22	EPS	44.3 %	0.35	0.25	-0.85	0.65	0.84	1.13	1.75
Suss Microtec SE CDAX (normalised)	EPS adj.	44.3 %	0.35	0.69	-0.11	0.78	0.84	1.13	1.75
Rel. Performance vs CDAX:	DPS	25.0 %	0.00	0.00	0.00	0.00	0.16	0.20	0.25
	Dividend Yield		n.a.	n.a.	n.a.	n.a.	0.7 %	1.4 %	1.8 %
1 month: -0.3 %	FCFPS		0.15	-0.26	-1.93	2.47	0.77	-0.02	1.25
6 months: -23.3 %	FCF / Market cap		1.3 %	-2.0 %	-19.8 %	19.2 %	3.2 %	-0.1 %	9.0 %
Year to date: -16.2 %	EV / Sales		n.a.	1.1 x	1.0 x	0.9 x	1.6 x	0.8 x	0.6 x
Trailing 12 months: -27.2 %	EV / EBITDA		n.a.	14.8 x	n.a.	8.2 x	14.5 x	6.2 x	3.9 x
÷	EV / EBIT adj.		n.a.	21.4 x	445.7 x	10.1 x	19.1 x	7.7 x	4.6 x
Company events:	P/E		34.4 x	53.5 x	n.a.	19.8 x	28.6 x	12.3 x	7.9 x
31.05.22 AGM	FCF Potential Yield		n.a.	2.3 %	-4.8 %	13.8 %	5.4 %	11.3 %	17.9 %
24.06.22 Warburg Highlights	Net Debt		-28.2	-23.1	24.0	-13.9	-28.4	-25.0	-45.1
04.08.22 Q2	ROCE (NOPAT)		6.9 %	4.5 %	n.a.	9.3 %	13.0 %	15.7 %	21.8 %
10.11.22 Q3	Guidance: 2	2022: Sales: 2	70-300m; EE	BIT 8.5-10.5%	%				

Malte Schaumann mschaumann@warburg-research.com +49 40 309537-170

Analyst






Company Background

- Globally leading manufacturer of systems for the MEMS, advanced packaging, 3D IC and LED niche markets with the product segments lithography (mask aligner,coater), bonder and equipment to clean photomasks.
- MEMS integrate electronic and mechanical components. Fields of application are e.g. pressure sensors (e.g. in tyre pressure control systems) or position and acceleration sensors (e.g. smartphones, tablet PCs).
- Advanced packaging is a special packaging process used as an alternative to the classic wire bonding ("flip chip") for semiconductors
 where these are directly bonded to the substrate without wire connections.
- 3D packaging is a solution to the increasingly difficult ongoing structural downsizing of semiconductors. CMOS image sensors are an early field of application. This market offers enormous growth potential for SÜSS.
- The majority of production is located at two sites in Germany (Garching, Sternenfels) which offer ample capacity for anticipated growth. SÜSS has ca. 900 employees.

Competitive Quality

- SÜSS consistently focuses on the core topics (precision, reliability and low total cost of ownership) in all segments and gears the products to the customers' needs.
- The 60-year company history and the consistently high product quality have firmly established SÜSS as a brand-name in the addressed markets.
- This and the global service network make the company a preferred supplier for production equipment in particular.
- As the respective markets have a niche character, SÜSS usually only has to face moderate competition and rarely has to compete with the major suppliers of the sector.
- This combined with the high product complexity poses a major barrier to market entry and secures the company a leading position in the respective markets.





DCF model														
	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	
Sales	300.0	355.0	370.0	399.6	427.6	453.2	475.9	499.7	519.7	540.5	562.1	573.3	581.9	
Sales change	13.9 %	18.3 %	4.2 %	8.0 %	7.0 %	6.0 %	5.0 %	5.0 %	4.0 %	4.0 %	4.0 %	2.0 %	1.5 %	1.8 %
EBIT	31.0	47.6	50.9	59.9	64.1	68.0	71.4	75.0	78.0	81.1	84.3	86.0	87.3	
EBIT-margin	10.3 %	13.4 %	13.8 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	
Tax rate (EBT)	29.2 %	29.4 %	29.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	
NOPAT	21.9	33.6	35.9	42.9	45.9	48.6	51.0	53.6	55.7	58.0	60.3	61.5	62.4	
Depreciation	7.9	8.5	8.5	12.0	12.0	12.7	13.3	14.0	14.6	15.1	15.7	16.1	16.3	
in % of Sales	2.6 %	2.4 %	2.3 %	3.0 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	18.3	6.4	5.8	4.7	8.7	8.0	7.0	7.4	6.2	6.4	6.7	3.5	2.7	
- Capex	11.6	11.6	11.5	22.8	12.8	13.6	14.3	15.0	15.6	16.2	16.9	17.2	17.5	
Capex in % of Sales	3.9 %	3.3 %	3.1 %	3.2 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-0.1	24.1	27.1	27.4	36.3	39.7	43.1	45.2	48.5	50.4	52.5	56.9	58.6	60
PV of FCF	-0.1	22.1	22.8	21.2	25.8	26.0	25.8	24.9	24.5	23.4	22.4	22.3	21.1	303
share of PVs		7.69 %						40.77	7 %					51.54 %
Model parameter							Valuat	on (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20)34e	28	5			
								al Value		30				
Debt ratio	4.00 %		Financial S	0		1.10		al liabilitie		1	8			
Cost of debt (after tax)	2.9 %		Liquidity (s	hare)		1.30		n liabilities			5			
Market return	7.50 %		Cyclicality			1.60	Hybrid	•			0			
Risk free rate	2.00 %		Transpare	псу		1.10		y interest	4 4 -		0			
			Others			1.40	Liquidit	val. of inv	esiments		0 7	No. of sha	roo (m)	19.1
WACC	8.90 %		Beta			1 20		,		61		-	. ,	
WACC	0.90 %		Deld			1.30	Equity	value		61	2	Value per	snare (E	UR) 32.03

Sensitivity Value per Share (EUR)

		Terminal C	Growth								Delta EBIT	-margin					
Beta	WACC	1.00 %	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.49	9.9 %	26.75	27.08	27.43	27.81	28.20	28.62	29.07	1.49	9.9 %	24.53	25.62	26.71	27.81	28.90	29.99	31.09
1.39	9.4 %	28.52	28.92	29.33	29.78	30.25	30.76	31.30	1.39	9.4 %	26.28	27.45	28.61	29.78	30.94	32.11	33.27
1.35	9.1 %	29.49	29.92	30.38	30.87	31.39	31.95	32.55	1.35	9.1 %	27.25	28.46	29.66	30.87	32.07	33.28	34.48
1.30	8.9 %	30.52	30.99	31.50	32.03	32.61	33.23	33.89	1.30	8.9 %	28.29	29.54	30.78	32.03	33.28	34.53	35.77
1.25	8.6 %	31.63	32.14	32.69	33.29	33.92	34.61	35.35	1.25	8.6 %	29.41	30.70	31.99	33.29	34.58	35.87	37.16
1.21	8.4 %	32.81	33.37	33.98	34.64	35.34	36.10	36.93	1.21	8.4 %	30.61	31.95	33.29	34.64	35.98	37.32	38.66
1.11	7.9 %	35.43	36.12	36.87	37.67	38.55	39.50	40.54	1.11	7.9 %	33.32	34.77	36.22	37.67	39.13	40.58	42.03

Growth estimate slightly below company target of EUR 400m by 2025

• Sustainable EBIT margin of 15% anticipated...



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2017	2018	2019	2020	2021	2022e	2023e
Net Income before minorities	n.a.	4.8	-16.3	12.3	16.0	21.6	33.4
+ Depreciation + Amortisation	n.a.	4.8	8.6	7.8	7.1	7.9	8.5
 Net Interest Income 	n.a.	-0.1	-0.4	-0.4	-0.5	-0.3	-0.2
 Maintenance Capex 	n.a.	2.5	2.7	2.7	2.7	2.7	2.7
+ Other	n.a.	-2.0	0.0	14.2	2.6	0.0	0.0
= Free Cash Flow Potential	n.a.	5.3	-10.0	32.0	23.4	27.1	39.4
FCF Potential Yield (on market EV)	n/a	2.3 %	-4.8 %	13.8 %	5.4 %	11.3 %	17.9 %
WACC	8.90 %	8.90 %	8.90 %	8.90 %	8.90 %	8.90 %	8.90 %
= Enterprise Value (EV)	n.a.	232.5	210.4	232.3	430.1	240.0	219.9
= Fair Enterprise Value	n.a.	59.2	n.a.	359.8	263.2	305.0	443.0
- Net Debt (Cash)	n.a.	-33.8	-33.8	-33.8	-33.8	-30.3	-50.4
- Pension Liabilities	n.a.	5.3	5.3	5.3	5.3	5.3	5.3
- Other	n.a.	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 	n.a.	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	n.a.	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	n.a.	87.6	n.a.	388.2	291.6	330.0	488.1
Number of shares, average	19.1	19.1	19.1	19.1	19.1	19.1	19.1
= Fair value per share (EUR)	n.a.	4.58	n.a.	20.31	15.26	17.26	25.53
premium (-) / discount (+) in %						24.6 %	84.2 %
Sensitivity Fair value per Share (E	UR)						
1.	1.90 % n.a.	3.80	n.a.	15.58	11.79	13.25	19.70
10).90 % n.a.	4.02	n.a.	16.87	12.74	14.35	21.30
9	9.90 % n.a.	4.27	n.a.	18.42	13.88	15.67	23.21
	3.90 % n.a.	4.58	n.a.	20.31	15.26	17.26	25.53
	7.90 % n.a.	4.98	n.a.	22.71	17.01	19.30	28.49
	6.90 % n.a.	5.48	n.a.	25.79	19.26	21.91	32.28
ł	5.90 % n.a.	6.16	n.a.	29.91	22.28	25.40	37.35

• Increasing sales and margins result in higher value indications in coming years



Valuation							
	2017	2018	2019	2020	2021	2022e	2023e
Price / Book	1.8 x	1.8 x	1.5 x	1.8 x	2.9 x	1.5 x	1.3 x
Book value per share ex intangibles	5.69	6.42	5.52	5.92	6.95	7.83	9.38
EV / Sales	n.a.	1.1 x	1.0 x	0.9 x	1.6 x	0.8 x	0.6 x
EV / EBITDA	n.a.	14.8 x	n.a.	8.2 x	14.5 x	6.2 x	3.9 x
EV / EBIT	n.a.	21.4 x	n.a.	11.4 x	19.1 x	7.7 x	4.6 x
EV / EBIT adj.*	n.a.	21.4 x	445.7 x	10.1 x	19.1 x	7.7 x	4.6 x
P / FCF	79.7 x	n.a.	n.a.	5.2 x	31.2 x	n.a.	11.1 x
P/E	34.4 x	53.5 x	n.a.	19.8 x	28.6 x	12.3 x	7.9 x
P / E adj.*	34.4 x	19.4 x	n.a.	16.5 x	28.6 x	12.3 x	7.9 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	0.7 %	1.4 %	1.8 %
FCF Potential Yield (on market EV)	n.a.	2.3 %	-4.8 %	13.8 %	5.4 %	11.3 %	17.9 %
*Adjustments made for: -							

Company Specific Items							
	2017	2018	2019	2020	2021	2022e	2023e
Order entry	200.3	191.0	219.2	281.1	336.0	350.0	0.0
Order backlog	133.0	0.0	93.2	120.1	193.3	243.3	0.0

COMMENT Published 13.05.2022 5



50.0 %

40.0 %

30.0 %

20.0 %

10.0 %

0.0 %

-10.0 %

-20.0 %

-30.0 %


Consolidated profit and loss

In EUR m	2017	2018	2019	2020	2021	2022e	2023e
Sales	166.5	203.9	213.8	252.1	263.4	300.0	355.0
Change Sales yoy	-6.2 %	22.5 %	4.8 %	17.9 %	4.5 %	13.9 %	18.3 %
COGS	107.0	136.7	164.1	168.4	169.2	192.0	227.2
Gross profit	59.5	67.3	49.7	83.7	94.2	108.0	127.8
Gross margin	35.7 %	33.0 %	23.3 %	33.2 %	35.8 %	36.0 %	36.0 %
Research and development	15.2	18.3	20.2	19.8	22.1	26.5	27.5
Sales and marketing	19.6	21.9	22.9	23.5	24.9	25.8	27.0
Administration expenses	13.4	15.9	18.9	20.8	22.9	24.0	25.0
Other operating expenses	3.8	3.5	3.2	3.4	5.9	0.7	0.7
Other operating income	6.3	3.2	1.7	4.3	4.2	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	18.0	15.7	-5.2	28.2	29.6	38.9	56.1
Margin	10.8 %	7.7 %	-2.4 %	11.2 %	11.2 %	13.0 %	15.8 %
Depreciation of fixed assets	2.8	3.6	7.3	7.1	6.4	7.0	7.5
EBITA	15.1	12.1	-12.5	21.1	23.2	31.9	48.6
Amortisation of intangible assets	1.2	1.2	1.2	0.7	0.7	0.9	1.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	13.9	10.9	-13.8	20.4	22.6	31.0	47.6
Margin	8.3 %	5.3 %	-6.4 %	8.1 %	8.6 %	10.3 %	13.4 %
EBIT adj.	13.9	10.9	0.5	23.0	22.6	31.0	47.6
Interest income	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.2	0.2	0.4	0.4	0.5	0.3	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	13.8	10.7	-14.1	20.0	22.1	30.7	47.4
Margin	8.3 %	5.3 %	-6.6 %	7.9 %	8.4 %	10.2 %	13.4 %
Total taxes	7.0	6.0	2.1	7.7	6.1	9.1	14.0
Net income from continuing operations	6.7	4.8	-16.3	12.3	16.0	21.6	33.4
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	6.7	4.8	-16.3	12.3	16.0	21.6	33.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	6.7	4.8	-16.3	12.3	16.0	21.6	33.4
Margin	4.0 %	2.3 %	-7.6 %	4.9 %	6.1 %	7.2 %	9.4 %
Number of shares, average	19.1	19.1	19.1	19.1	19.1	19.1	19.1
EPS	0.35	0.25	-0.85	0.65	0.84	1.13	1.75
EPS adj.	0.35	0.69	-0.11	0.78	0.84	1.13	1.75
*Adjustments made for:							

Guidance: 2022: Sales: 270-300m; EBIT 8.5-10.5%

Financial Ratios

	2017	2018	2019	2020	2021	2022e	2023e
Total Operating Costs / Sales	27.4 %	27.7 %	29.7 %	25.1 %	27.2 %	25.7 %	22.6 %
Operating Leverage	-4.0 x	-1.0 x	n.a.	n.a.	2.3 x	2.7 x	2.9 x
EBITDA / Interest expenses	86.8 x	90.3 x	n.m.	66.6 x	63.5 x	129.7 x	280.5 x
Tax rate (EBT)	51.2 %	55.4 %	-15.2 %	38.3 %	27.5 %	29.5 %	29.5 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	19.1 %	17.7 %	14.3 %
Sales per Employee	254,235	231,740	228,174	263,139	237,760	260,870	295,833




Consolidated balance she




Consolidated balance sheet							
In EUR m	2017	2018	2019	2020	2021	2022e	2023e
Assets							
Goodwill and other intangible assets	18.2	17.7	19.9	23.4	24.0	24.3	24.4
thereof other intangible assets	2.5	1.9	4.2	5.0	5.6	5.8	5.9
thereof Goodwill	15.6	15.7	15.7	18.3	18.4	18.4	18.4
Property, plant and equipment	23.3	26.2	33.9	40.4	44.5	48.0	51.0
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	41.5	43.9	53.8	63.7	68.5	72.3	75.4
Inventories	97.9	93.5	75.0	73.0	99.5	100.0	104.4
Accounts receivable	19.6	25.1	50.2	48.0	47.4	49.3	48.6
Liquid assets	36.5	30.7	10.3	40.8	52.1	45.8	65.9
Other short-term assets	6.4	6.4	10.6	5.9	11.6	10.2	10.2
Current assets	160.5	155.7	146.1	167.7	210.7	205.3	229.1
Total Assets	202.0	199.6	199.9	231.4	279.2	277.6	304.5
Liabilities and shareholders' equity							
Subscribed capital	19.1	19.1	19.1	19.1	19.1	19.1	19.1
Capital reserve	110.3	122.9	106.6	119.0	135.0	135.0	135.0
Retained earnings	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other equity components	-2.4	-1.5	-0.3	-1.6	2.8	20.0	49.7
Shareholders' equity	127.0	140.4	125.4	136.5	156.9	174.1	203.8
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	127.0	140.4	125.4	136.5	156.9	174.1	203.8
Provisions	7.4	10.3	10.2	10.9	11.2	11.2	11.2
thereof provisions for pensions and similar obligations	4.7	5.1	6.0	6.4	5.3	5.3	5.3
Financial liabilities (total)	3.5	2.5	28.3	20.5	18.3	15.5	15.5
Short-term financial liabilities	1.0	1.0	10.4	1.4	1.2	1.2	1.2
Accounts payable	7.3	9.0	10.0	9.8	24.4	12.3	14.6
Other liabilities	56.8	37.3	26.0	53.7	68.4	64.5	59.5
Liabilities	75.0	59.1	74.5	94.9	122.3	103.5	100.8
Total liabilities and shareholders' equity	202.0	199.6	199.9	231.4	279.2	277.6	304.5

Financial Ratios

	2017	2018	2019	2020	2021	2022e	2023e
Efficiency of Capital Employment							
Operating Assets Turnover	1.8 x	1.7 x	1.5 x	2.0 x	2.0 x	1.9 x	2.2 x
Capital Employed Turnover	1.7 x	1.7 x	1.4 x	2.1 x	2.1 x	2.0 x	2.2 x
ROA	16.2 %	10.9 %	-30.3 %	19.4 %	23.4 %	29.9 %	44.3 %
Return on Capital							
ROCE (NOPAT)	6.9 %	4.5 %	n.a.	9.3 %	13.0 %	15.7 %	21.8 %
ROE	5.3 %	3.6 %	-12.2 %	9.4 %	10.9 %	13.1 %	17.7 %
Adj. ROE	5.3 %	9.9 %	-1.6 %	11.4 %	10.9 %	13.1 %	17.7 %
Balance sheet quality							
Net Debt	-28.2	-23.1	24.0	-13.9	-28.4	-25.0	-45.1
Net Financial Debt	-33.0	-28.2	18.0	-20.3	-33.8	-30.3	-50.4
Net Gearing	-22.2 %	-16.4 %	19.2 %	-10.2 %	-18.1 %	-14.4 %	-22.1 %
Net Fin. Debt / EBITDA	n.a.						
Book Value / Share	6.6	7.3	6.6	7.1	8.2	9.1	10.7
Book value per share ex intangibles	5.7	6.4	5.5	5.9	7.0	7.8	9.4



Book Value per Share in EUR



COMMENT

Published 13.05.2022

7

Consolidated cash flow statement




In EUR m	2017	2018	2019	2020	2021	2022e	2023e
Net income	6.7	4.8	-16.3	12.3	16.0	21.6	33.4
Depreciation of fixed assets	2.8	3.6	7.3	7.1	6.4	7.0	7.5
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.2	1.2	1.2	0.7	0.7	0.9	1.0
Increase/decrease in long-term provisions	0.3	0.2	0.1	0.4	-1.2	0.0	0.0
Other non-cash income and expenses	-0.4	2.9	5.2	9.1	7.8	0.0	0.0
Cash Flow before NWC change	10.7	12.7	-2.4	29.5	29.7	29.5	41.9
Increase / decrease in inventory	-28.2	-29.8	4.6	9.8	-29.5	-0.5	-4.4
Increase / decrease in accounts receivable	2.9	-1.9	-25.0	2.1	1.9	-1.9	0.7
Increase / decrease in accounts payable	23.9	1.7	-8.0	13.7	22.3	-16.0	-2.7
Increase / decrease in other working capital positions	0.0	19.3	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-1.3	-10.8	-28.4	25.6	-5.4	-18.3	-6.4
Net cash provided by operating activities [1]	9.4	1.9	-30.8	55.1	24.3	11.2	35.5
Investments in intangible assets	0.5	0.6	3.4	1.1	1.2	1.1	1.1
Investments in property, plant and equipment	6.0	6.3	5.7	8.0	8.5	10.5	10.5
Payments for acquisitions	0.0	0.0	0.0	-3.3	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	-6.5	-6.9	-6.1	-11.2	-9.6	-11.6	-11.6
Change in financial liabilities	-1.0	-1.0	16.4	-13.3	-3.8	-2.8	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	-3.1	-3.8
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	-1.0	-1.0	16.4	-13.3	-3.8	-5.9	-3.8
Change in liquid funds [1]+[2]+[3]	1.9	-6.0	-20.5	30.7	10.9	-6.2	20.1
Effects of exchange-rate changes on cash	-1.0	0.2	0.1	-0.2	0.0	0.0	0.0
Cash and cash equivalent at end of period	36.5	30.7	10.3	40.8	51.7	45.8	65.9

Financial Ratios


	2017	2018	2019	2020	2021	2022e	2023e
	2017	2010	2019	2020	2021	20226	20236
Cash Flow							
FCF	2.9	-5.0	-36.9	47.2	14.7	-0.4	23.9
Free Cash Flow / Sales	1.7 %	-2.5 %	-17.3 %	18.7 %	5.6 %	-0.1 %	6.7 %
Free Cash Flow Potential	n.a.	5.3	-10.0	32.0	23.4	27.1	39.4
Free Cash Flow / Net Profit	43.1 %	-105.1 %	226.9 %	382.4 %	91.9 %	-1.7 %	71.6 %
Interest Received / Avg. Cash	0.2 %	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	5.2 %	5.8 %	2.5 %	1.7 %	2.4 %	1.8 %	1.3 %
Management of Funds							
Investment ratio	3.9 %	3.4 %	4.2 %	3.6 %	3.7 %	3.9 %	3.3 %
Maint. Capex / Sales	n.a.	1.2 %	1.3 %	1.1 %	1.0 %	0.9 %	0.8 %
Capex / Dep	159.2 %	143.2 %	105.6 %	117.1 %	136.4 %	146.8 %	136.5 %
Avg. Working Capital / Sales	42.6 %	39.5 %	46.1 %	37.9 %	33.0 %	32.6 %	31.0 %
Trade Debtors / Trade Creditors	269.4 %	278.4 %	501.1 %	487.7 %	194.0 %	400.8 %	332.9 %
Inventory Turnover	1.1 x	1.5 x	2.2 x	2.3 x	1.7 x	1.9 x	2.2 x
Receivables collection period (days)	43	45	86	69	66	60	50
Payables payment period (days)	25	24	22	21	53	23	23
Cash conversion cycle (Days)	215	222	210	151	155	170	154

CAPEX and Cash Flow in EUR m





Working Capital



COMMENT

2017

2018 2019

Published 13.05.2022

2020 2021 2022e 2023e

FCF (m) - Free Cash Flow / Sales

8



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).



SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.)

KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in
 -2- the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.

MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of

confidential business information.

-4-

- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
SÜSS MicroTec	5	http://www.mmwarburg.com/disclaimer/disclaimer en/DE000A1K0235.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.		
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.		
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.		
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.		

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	171	81
Hold	36	17
Sell	3	1
Rating suspended	2	1
Total	212	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	50	86
Hold	6	10
Sell	0	0
Rating suspended	2	3
Total	58	100

PRICE AND RATING HISTORY SÜSS MICROTEC AS OF 13.05.2022



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables Jonas Blum Telco, Media, Construction **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech. Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg **Financial Services** Mustafa Hidir Automobiles, Car Suppliers Thor Höfs Software IT

INSTITUTIONAL EQUITY SALES

mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-240 jblum@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-230 mhidir@warburg-research.com +49 40 309537-255 thoefs@warburg-research.com

+49 40 3282-2678

+49 40 309537-280

mrode@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com +49 69 5050-7400 kschilling@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2669 aeschweiler@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com

+49 40 3282-2634

+49 40 3282-2702

+49 40 3282-2700

+49 40 3282-2632

aschaper@mmwarburg.com

edust@mmwarburg.com

SALES TRADING

Marc Niemann

Klaus Schilling

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

United Kingdom, Ireland

Alexander Eschweiler

Germany, Luxembourg

Matthias Fritsch

United Kingdom

United Kingdom

Head of Equity Sales. Germany

Head of Equity Sales, Germany

Oliver Merckel Head of Sales Trading omerckel@mmwarburg.com Elyaz Dust Sales Trading Michael Ilgenstein Sales Trading milgenstein@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572 cklude@mmwarburg.com Macro Research Our research can be found under: Warburg Research research.mmwarburg.com/en/index.html Bloomberg **RESP MMWA GO** FactSet www.factset.com

For access please contact: Andrea Schaper

Sales Assistance

Kerstin Muthig Sales Assistance

Refinitiv

Capital IQ

Real Estate **Thilo Kleibauer** Retail, Consumer Goods Eggert Kuls Engineering Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate Cansu Tatar

Philipp Kaiser

Cap. Goods, Engineering Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst Technology Andreas Wolf Software, IT

Maximilian Martin Austria, Poland **Christopher Seedorf** Switzerland

Sophie Hauer Roadshow/Marketing Juliane Niemann

Roadshow/Marketing

Marcel Magiera Sales Trading **Bastian Quast** Sales Trading Jörg Treptow Sales Trading

Dr. Christian Jasperneite Investment Strategy

+49 40 3282-2694 jniemann@mmwarburg.com +49 40 3282-2662

mmagiera@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

> www.refinitiv.com www.capitaliq.com

+49 40 3282-2703 kmuthig@mmwarburg.com



+49 40 309537-260

+49 40 309537-257

+49 40 309537-256

+49 40 309537-246

+49 40 309537-170

+49 40 309537-250

+49 40 309537-265

+49 40 309537-248

+49 40 309537-259

+49 40 309537-290

+49 40 309537-140

+49 69 5050-7413

+49 40 3282-2695

+49 69 5050-7417

shauer@mmwarburg.com

mmartin@mmwarburg.com

cseedorf@mmwarburg.com

pkaiser@warburg-research.com

tkleibauer@warburg-research.com

aplaesier@warburg-research.com

oschwarz@warburg-research.com

sstippig@warburg-research.com

ctatar@warburg-research.com

mtonn@warburg-research.com

awolf@warburg-research.com

rvanderhorst@warburg-research.com

mschaumann@warburg-research.com

ekuls@warburg-research.com